Goodrich Katherine 4

What Happened Katherine Goodrich, a non-employee director of Tarsus Pharmaceuticals (TARS), was granted equity awards on 2026-06-25 consisting of 3,837 stock options and 2,417 restricted stock units (RSUs), for a total of 6,254 units. Both grants were reported at $0.00 per unit (award/grant). The options and RSUs are awards as part of director compensation rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filed within the normal reporting window).
• Grants: 3,837 options (derivative) and 2,417 RSUs — total 6,254 units. Reported price: $0.00 (award).
• Vesting: Options vest in full on the one‑year anniversary of the grant; RSUs convert to one share each and vest in full on the one‑year anniversary, both subject to continued service as a non‑employee director (Footnotes F1–F3).
• Transaction code: A (award/grant). No 10b5‑1 plan, tax‑withholding sale, or late filing indicated in the provided report.
• Shares owned after the transaction: not specified in the provided extract.

Context These grants appear to be standard annual equity compensation for service on the board, not purchases or sales that directly reveal buying/selling sentiment. The options are derivative awards that only convert to stock upon vesting and any subsequent exercise; the RSUs are contingent rights to receive shares upon vesting. Such awards are common for non‑employee directors and should be viewed as compensation rather than an immediate market investment.